Ulusal Romatoloji Dergisi / Journal of Turkish Society for Rheumatology
 
 
p-ISSN: 2651-2653
e-ISSN: 2651-2661
Editor-in-Chief
Haner Direskeneli
2018 Volume 10
 
 
Deomed Yayıncılık
 
 
 
Volume 10, Issue 2, December 2018
Page(s): 85-87
 
Recommendation
Received: May 28, 2018; Accepted: July 24, 2018; Published online: September 27, 2018
doi:10.2399/raed.18.18023; Copyright © 2018 Turkish Society for Rheumatology
Turkish Society for Rheumatology recommendations for biosimilar drugs
Ediz Dalkılıç (E-mail), Aşkın Ateş, Şeminur Haznedaroğlu, Göksal Keskin, Süleyman Serdar Koca, Zeynep Özbalkan, Taşkın Şentürk, Serdal Uğurlu, Ayten Yazıcı, Ahmet Gül
Turkish Society for Rheumatology, Recommendations for Biosimilar Drugs Committee
Summary
Biologic drugs revolutionized in the treatment of many inflammatory rheumatological diseases. After the expiry of the patent of approved biologic drug, biosimilar drugs become available and market in the treatment of rheumatological diseases. In this article, besides the effectiveness and safety issues, Turkish Society for Rheumatology recommend about the definition, naming, interchangeability and extrapolation of the biosimilar drugs.
Keywords: Turkish Society for Rheumatology, biosimilars
 
 
Reklam
 
   
RAED Dergisi / RAED Journal

Türkiye Romatoloji Derneği (TRD) yayın organıdır. Deomed Yayıncılık tarafından yayımlanmaktadır. / Official Publication of the Rheumatology Society of Turkey (TRD). Published by Deomed Publishing. Copyright © 2018, TRD.
Creative Commons License
RAED Dergisi çevrimiçi (online) sürümünde yayımlanan akademik içeriğin kullanım hakları, ilgili içerikte tersi belirtilmediği sürece Deomed Yayıncılık tarafından Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) lisansı aracılığıyla bedelsiz sunulmaktadır. / Except where otherwise noted, academic content of this online version of the journal by Deomed Publishing is licensed under the terms of Creative Commons Attribution-NoCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND3.0) License.